Impact of P53 and SIRT1 in Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2028-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sherief Abd-Elsalam
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Prediabetic subjects.

Exclusion Criteria:

• Confirmed diabetes.

• Hepatic or renal impairment.